Editorial: Influence of lifestyle factors in the management of diabetes mellitus

Editorial on the Research TopicInfluence of lifestyle factors in the management of diabetes mellitus Diabetes mellitus (DM) is a multi-factorial metabolic disease that affects approximately 462 million individuals, corresponding to 6.28% of the world's population (4.4% of those aged 15-49 years, 15% of those aged 50-69, and 22% of those aged 70+), with a prevalence rate of 6,059 cases per 100,000 (1).DM accounts for over 1 million deaths per year, making it the ninth leading cause of mortality (1).The DM burden is rising globally and at a much faster rate in developed regions, such as Western Europe, with equal gender distribution, and the incidence peaks at approximately 55 years of age (1).In this scenario, we expect a global prevalence of DM of approximately 7,079 individuals per 100,000 by 2030 (1).To date, the rising burden of DM is a major concern in healthcare worldwide, and there is a need for urgent public health and clinical preventive measures (1).In non-Western countries, in a cohort of 215,041 elderly adults living in China (102,692 men and 112,349 women), authors reported a prevalence of self-reported diabetes of approximately 8.7%, with the highest prevalence in Beijing (20.8%) and the lowest prevalence in Xizang (0.9%), (Hu et al.).Notably, urban areas, older age, female, higher income, poor sleep quality, and some other factors were potential risk factors for diabetes (Hu et al.).Conversely, sociodemographic and behavioral factors could be linked to the low awareness of DM medication (Khoiry et al.).Indeed, irregular blood glucose monitoring without any comorbidity, never having any general medical checkup, 26-35 years of age, 36-45 years of age, and having no health insurance coverage were significantly associated with low awareness of diabetes medication (Khoiry et al.).Notably, the complexity of oral anti-diabetic drug (OAD) regimens could affect the quality of life (QOL) and treatment satisfaction (Chang et al.). Indeed, a study conducted in Taiwan showed a significantly greater effect on QOL among patients with fewer OAD classes and higher treatment satisfaction (Chang et al.).Parallelly, new anti-DM treatments could effectively ameliorate the glucose and blood lipid metabolism via effects on the intestinal flora in type 2 DM (T2DM) patients (Peng, X. et al.).In this context, the Frontiers in Endocrinology frontiersin.